Figure 1.
Trial flow chart.
Table 1.
Baseline data stratified according to treatment allocation.
Figure 2.
Changes in left ventricular ejection fraction and LDL cholesterol.
The left panel illustrates the change in left ventricular ejection fraction (LVEF) stratified by treatment allocation. There was no difference in the change in LVEF between the two groups as analyzed by an independent group t-test (p = 0.94). The right panel illustrates the change in LDL cholesterol stratified by treatment allocation. The fall in LDL cholesterol occurred in patients allocated to rosuvastatin (p for difference < 0.001). Boxes: 25–75 percentiles; whiskers: 10–90 percentiles.
Figure 3.
Correlation between left ventricular ejection fraction as measured by echocardiography and as measured by magnetic resonance imaging.
Data from baseline and follow-up are pooled. The Pearson correlation coefficient between results obtained by magnetic resonance imaging (MRI) and results obtained by echocardiography was 0.82 (p < 0.001).
Table 2.
Results from cardiac imaging exams, New York Heart Association (NYHA) classification and quality of life measurements.
Figure 4.
Changes in markers of inflammation and extracellular matrix turnover.
Changes in C-reactive protein (CRP), soluble tumor necrosis factor receptor type 1 (sTNF-R1), and procollagen type I and III N-terminal pro-peptides (PINP and PIIINP) stratified by treatment allocation. p-values for between-group differences in changes were computed by independent group t-tests. While PINP increased more in patients treated with rosuvastatin as compared to patients treated with placebo (p = 0.03), treatment did not affect any of the other markers of inflammation or matrix remodeling. Boxes: 25–75 percentiles; whiskers: 5–95 percentiles.
Table 3.
Results of blood tests.